Euroapi SA (EAPI) AI Stock Analysis

• Market Cap: €296.60M
• Dividend Yield: N/A
• Average Volume (3M): 104.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -10.00%
• EPS Growth: 31.03%
• Country: FR
• Employees: 3,187
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -1.01
• Shares Outstanding: 95,589,775
• 10 Day Avg. Volume: 85,281
• 30 Day Avg. Volume: 104,094
• PEG Ratio: 14.73
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.00
• Price Target Upside: 2.04% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: €3.00 ▲(2.04%Upside)

Euroapi SA's overall stock score reflects its financial challenges, particularly in profitability and revenue growth, and poor valuation metrics due to a negative P/E ratio. The technical analysis provides a slightly more positive outlook, with stock prices above certain moving averages and a neutral RSI. Continued focus on improving financial performance and profitability will be essential for enhancing the stock's attractiveness.

Euroapi SA Business Overview & Revenue Model

Company Description

Euroapi SA (EAPI) is a leading European player in the pharmaceutical sector, specializing in the development, production, and supply of active pharmaceutical ingredients (APIs). The company operates across a broad spectrum of therapeutic areas, providing high-quality APIs that are essential components in the manufacturing of medicines. Euroapi serves a diverse range of clients, including pharmaceutical and biotechnology companies, across both generic and branded drug markets.

How the Company Makes Money

Euroapi SA generates revenue primarily through the sale of active pharmaceutical ingredients (APIs) to pharmaceutical and biotechnology companies. The company's key revenue streams include long-term supply agreements with major pharmaceutical firms, custom manufacturing services, and the development of proprietary APIs. Euroapi leverages its extensive manufacturing capabilities, research and development expertise, and strong industry relationships to maintain a competitive edge. Strategic partnerships and collaborations with leading pharmaceutical companies further enhance its market presence and contribute significantly to its earnings.

Euroapi SA Financial Statement Overview

Summary

Euroapi SA faces financial challenges with declining revenue and profitability issues. Despite a positive EBITDA margin and efficient cash flow generation, the negative revenue growth and net losses weigh heavily on the financial performance score. The balance sheet shows low leverage and a strong equity position, providing a base for potential recovery.

Income Statement

Euroapi SA has faced declining revenue over the past year, with a negative revenue growth rate of 9.78% from 2023 to 2024. The company is experiencing significant challenges in profitability, as indicated by negative EBIT and net profit margins. The gross profit margin also reflects a downward trend. Despite these challenges, the company has managed to maintain a positive EBITDA margin, offering some stability in operational performance.

Balance Sheet

The balance sheet shows a moderate level of stability with a debt-to-equity ratio of 0.07, indicating low leverage. The return on equity is negative due to net losses, but the equity ratio remains healthy at 66.01%, suggesting a strong capital base. The company has been reducing its debt, which is a positive sign for future financial flexibility.

Cash Flow

Euroapi SA's cash flow remains a mixed picture with a significant improvement in operating cash flow from 2023 to 2024. However, the free cash flow growth rate is negative, reflecting high capital expenditures. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income, but the free cash flow to net income ratio is low.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	919.20M	1.02B	980.90M	892.80M	944.60M
Gross Profit	142.40M	164.60M	176.90M	109.10M	90.50M
EBITDA	-34.70M	71.00M	71.20M	62.40M	61.60M
Net Income	-130.60M	-189.70M	-15.10M	-15.80M	-6.30M
Balance Sheet
Total Assets	1.49B	1.61B	1.74B	1.62B	1.60B
Cash, Cash Equivalents and Short-Term Investments	73.00M	34.50M	74.50M	29.30M	153.90M
Total Debt	69.10M	225.50M	120.80M	24.10M	73.40M
Total Liabilities	506.00M	684.70M	625.90M	607.00M	611.60M
Stockholders Equity	983.50M	927.70M	1.11B	1.01B	989.40M
Cash Flow
Free Cash Flow	14.90M	-127.70M	-122.60M	-17.10M	8.40M
Operating Cash Flow	122.90M	5.10M	44.80M	71.50M	96.80M
Investing Cash Flow	-108.00M	-137.30M	-167.40M	-87.90M	-88.30M
Financing Cash Flow	26.50M	92.20M	187.80M	26.50M	-8.40M

Euroapi SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.94
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EAPI, the sentiment is Negative. The current price of 2.94 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 3.05, and below the 200-day MA of 3.07, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.80 is Neutral, neither overbought nor oversold. The STOCH value of 5.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EAPI.

Euroapi SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALERS	58 Neutral	€253.64M	63.58	2.27%	―	18.89%	-20.75%
Sector *	54 Neutral	€4.79B	16.30	-48.29%	2.23%	15.31%	-8.27%
EAPI	50 Neutral	€296.60M	―		―	-10.00%	31.03%
ALMDT	42 Neutral	€35.77M	―		―	3.25%	-2.07%